Clinical experience with risperidone and memantine in the treatment of Huntington's disease

Journal of the National Medical Association

Volumn 98, Issue 8, 2006, Pages 1353-1355

  Cankurtaran, Eylem Sahin ^a,b,c   Ozalp, Elvan ^a,b   Soygur, Haldun ^a,b   Cakir, Aysegul ^a,c  

^a Ankara Oncology Training and Research Hospital ^*

^b ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c Ankara Onkoloji Egitim Arastirma H   (Turkey)

Author keywords

Cognitive symptoms; Huntington's disease; Psychiatry

Indexed keywords

MEMANTINE; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; CHOREA; COGNITIVE DEFECT; DISEASE SEVERITY; FEMALE; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PSYCHOSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; COGNITION; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; MEMANTINE; RISPERIDONE;

EID: 33746687898     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Gilliam TC, Tanzi RE, Haines JL, et al. Localization of the Huntington's disease gene to small segment of chromosome 4 flanked by D4S10 and the telomere. Cell. 1987;50:565-568.
2. Sharp AH, Ross CA. Neurobiology of Huntington's Disease. Neurobioi Dis. 1996;3:3-15.
3. Dallocchio C, Buffa C, Tinelli C, et al. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacoly 1999;19:101-103.
4. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol. 2002;9:182-183.
5. Meco G, Bonifati V, Alessandri B, et al. Risperidone in Huntington's disease (letter). Hum Psychopharmacol. 1995;10:353-354.
6. Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162(10):1888-1895.
7. Mc Geer EG, McGeer PL, Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 1998;139:381-383.
8. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;60:996-998.
9. Beister A, Kraus P, Dose M, et al. The N-Methyl-D- aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl. 2004;68:117-122.
10. Lemiere J, Ducruyenaere M, Evers-Kiebooms G, et al. Cognitive changes in patients with Huntington's disease and asymptomatic carriers of the HD mutation: a longitudinal follow-up study. J Neurol. 2004;251(8):935-942.